Transaction DateRecipientSharesTypePriceValue
22nd December 2020Partners L P/Il Bvf11,278Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf654,215Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf1,944Conversion of derivative$0.00
22nd December 2020Ventures Iv, L.P. 5 Am20,000Open or private sale$12.82$256,400.00
22nd December 2020Ventures Iv, L.P. 5 Am480,000Open or private sale$12.82$6,153,600.00
22nd December 2020Partners L P/Il Bvf509,410Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf97,615Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf15,166Conversion of derivative$0.00
22nd December 2020Yujiro S Hata8,000Exercise of derivative$4.31$34,480.00
18th December 2020Michael P. Dillon7,750Exercise of derivative$4.31$33,402.50
Ideaya Biosciences
Ideaya Biosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


IDEA Biosciences, Inc. develops cancer therapeutics. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.


Ticker: IDYA
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1676725
Employees: 47
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals